The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 30, 2024

Filed:

Dec. 26, 2018
Applicant:

Nanjing Genscript Biotech Co., Ltd., Jiangsu, CN;

Inventors:

Zhongdao Li, Jiangsu, CN;

Lixin Song, Jiangsu, CN;

Wang Zhang, Jiangsu, CN;

Yafeng Zhang, Jiangsu, CN;

Dongliang Wang, Jiangsu, CN;

Zhenyu Liu, Jiangsu, CN;

Fangliang Zhang, Jiangsu, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); C07K 14/5434 (2013.01); C07K 16/2827 (2013.01); C07K 2317/569 (2013.01); C07K 2319/30 (2013.01);
Abstract

Provided is a fusion protein dimer using an antibody Fc region as the backbone, comprising a first and a second polypeptide chain. The first polypeptide chain comprises a first antibody Fc region and one or more single-domain antibodies fused to the first antibody Fc region. The second polypeptide chain comprises a second antibody Fc region and one or more single domain antibodies fused to the second antibody Fc region. The first polypeptide chain and/or the second polypeptide chain further comprise a cytokine fused to the Fc region of the respective antibody. Further provided is use of the fusion protein dimer in preparing an immunotherapeutic drug for treating tumors. The Fc fusion protein heterodimer not only increases the activity of a single domain antibody, but also significantly improves the biological activity of a cytokine. Further, by means of the targeting specificity of the antibody, the targeted transport of the cytokine is effectively enhanced, and cytotoxicity is attenuated, thereby obtaining better anti-tumor potential.


Find Patent Forward Citations

Loading…